Comparative Pharmacology
Head-to-head clinical analysis: BUTRANS versus FYREMADEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTRANS versus FYREMADEL.
BUTRANS vs FYREMADEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist. It binds with high affinity to mu-opioid receptors, producing analgesic and opioid effects with a ceiling effect on respiratory depression.
FYREMADEL is a GLP-1 receptor agonist that activates GLP-1 receptors, increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner, and slows gastric emptying.
Apply one BUTRANS (buprenorphine) transdermal system to a clean, dry, non-irritated, and non-hairy area of the chest, back, flank, or upper arm. Initial dose: 5 mcg/h for opioid-naïve patients; titrate based on pain control and tolerability. Maximum dose: 20 mcg/h. Replace every 7 days. Rotate application sites.
100 mg orally twice daily.
None Documented
None Documented
Terminal half-life: 4-6 hours in healthy adults; prolonged to 12-18 hours in elderly or renal impairment
Terminal half-life: 12 hours (range 8–16 h) in healthy adults; prolonged in hepatic impairment.
Renal: 60-70% as unchanged drug and metabolites; biliary/fecal: 20-30%
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% other.
Category C
Category C
Opioid Analgesic
Opioid Analgesic